On July 5, Chief Judge Stark of the Delaware District issued a claim construction opinion in the pharmaceutical patent case of Noven v. Actavis.  The patent at issue is US Patent No. 8,231,906, “Transdermal estrogen device and delivery.” Like many US pharmaceutical patent cases, this one arises under the Hatch-Waxman framework, in which a generic manufacturer submits an Abbreviated New Drug Application to the FDA and thereby creates a constructive.. Read More